- Home
- SNN vs UTHR Comparison
SNN vs UTHR Comparison
Compare SNN & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNN
- UTHR
- Stock Information
- Founded
- SNN 1856
- UTHR 1996
- Country
- SNN United Kingdom
- UTHR United States
- Employees
- SNN N/A
- UTHR N/A
- Industry
- SNN Industrial Specialties
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- SNN Health Care
- UTHR Health Care
- Exchange
- SNN Nasdaq
- UTHR Nasdaq
- Market Cap
- SNN 15.2B
- UTHR 20.7B
- IPO Year
- SNN 1999
- UTHR 1999
- Fundamental
- Price
- SNN $33.34
- UTHR $455.08
- Analyst Decision
- SNN Hold
- UTHR Buy
- Analyst Count
- SNN 4
- UTHR 12
- Target Price
- SNN $33.50
- UTHR $495.08
- AVG Volume (30 Days)
- SNN 664.9K
- UTHR 586.0K
- Earning Date
- SNN 10-30-2025
- UTHR 10-29-2025
- Dividend Yield
- SNN 2.19%
- UTHR N/A
- EPS Growth
- SNN 59.91
- UTHR 16.08
- EPS
- SNN 0.56
- UTHR 26.38
- Revenue
- SNN $5,944,000,000.00
- UTHR $3,128,400,000.00
- Revenue This Year
- SNN $7.85
- UTHR $13.68
- Revenue Next Year
- SNN $5.43
- UTHR $5.63
- P/E Ratio
- SNN $59.75
- UTHR $17.02
- Revenue Growth
- SNN 5.35
- UTHR 13.50
- 52 Week Low
- SNN $23.69
- UTHR $266.98
- 52 Week High
- SNN $38.79
- UTHR $479.50
- Technical
- Relative Strength Index (RSI)
- SNN 34.58
- UTHR 60.85
- Support Level
- SNN $31.83
- UTHR $444.04
- Resistance Level
- SNN $33.60
- UTHR $456.41
- Average True Range (ATR)
- SNN 0.54
- UTHR 14.30
- MACD
- SNN -0.37
- UTHR 0.60
- Stochastic Oscillator
- SNN 26.67
- UTHR 62.81
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.